Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial ...

The firm believes VVD-159642 has the potential to treat a broad patient population, including those with RAS- and HER2-overexpressed tumors.

Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial evaluating VVD-159642, an investigational oral inhibitor designed to target RAS ...

VVD-159642, Vividion's fourth clinical-stage program stemming from its chemoproteomics discovery platform, is designed to improve patient outcomes by inhibiting RAS-PI3Ka, a key signaling pathway ...

Results showed that FGFR2 gene deletion led to significantly fewer precancerous lesions and delayed PDAC tumor formation ...

TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics ("BBOT" or the "Company"), a clinical-stage biopharmaceutical company ...

You will be redirected to our submission process. The RTK/RAS/RAF pathway remains a critical focus in cancer research due to its frequent dysregulation in various malignancies. Classical EGFR ...

REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...

Verastem (NASDAQ:VSTM – Get Free Report) and Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) are both small-cap medical ...

Shock!! Ninety-eight-year-old Eli the priest hears they lost the war; his sons are killed; the Ark of God is taken (1 Sam. 4:17,22); God's judgment (2:27-34); God deals with the Philistines (5:1-12; 6 ...

T细胞急性淋巴细胞白血病（T-ALL）是一种起源于T淋巴细胞前体的恶性血液肿瘤，约占儿童急性淋巴细胞白血病的15%-20%。近年来，儿童T-ALL整体治疗效果有所提升，但仍有约四分之一的患儿在治疗后复发，且复发后预后差，如何在诊断初期准确识别具有高复 ...